Neurocrine Biosciences CSO Jude Onyia Vests Performance RSUs with Tax Withholding

Executive Summary

On September 15, 2026, Neurocrine Biosciences, Inc. ($NBIX) filed a Form 4 on behalf of Chief Scientific Officer Jude Onyia. The report reflects the certification and vesting of Performance Restricted Stock Units (PRSUs) on September 11, 2026, followed by a standard disposition of shares to satisfy tax withholding obligations.

Transaction Breakdown

1. Performance RSU Vesting (Code A):

   • Shares Acquired: 3,587 shares of Common Stock
   • Price Per Share: $0.00
   • Nature: Direct
   • Details: Certified achievement of performance metrics under previously granted PRSUs.

2. Tax Withholding (Code F):

   • Shares Withheld: 1,936 shares
   • Price Per Share: $156.22
   • Total Value Withheld: $302,441.92
   • Details: Mandatory withholding by the issuer to cover tax obligations; no open-market sale took place.

Post-Transaction Holdings

Following these transactions, Jude Onyia directly holds 22,647 shares of Neurocrine Biosciences common stock.

Market Impact & Significance

The trading significance is assessed as Low. These transactions reflect non-discretionary equity award vesting and routine tax withholding rather than discretionary open-market buying or selling.